1. Home
  2. BCAB vs SYTA Comparison

BCAB vs SYTA Comparison

Compare BCAB & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • SYTA
  • Stock Information
  • Founded
  • BCAB 2007
  • SYTA N/A
  • Country
  • BCAB United States
  • SYTA Canada
  • Employees
  • BCAB N/A
  • SYTA N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • SYTA Telecommunications Equipment
  • Sector
  • BCAB Health Care
  • SYTA Telecommunications
  • Exchange
  • BCAB Nasdaq
  • SYTA Nasdaq
  • Market Cap
  • BCAB 31.5M
  • SYTA 29.0M
  • IPO Year
  • BCAB 2020
  • SYTA 2020
  • Fundamental
  • Price
  • BCAB $0.79
  • SYTA $3.07
  • Analyst Decision
  • BCAB Hold
  • SYTA
  • Analyst Count
  • BCAB 3
  • SYTA 0
  • Target Price
  • BCAB $1.00
  • SYTA N/A
  • AVG Volume (30 Days)
  • BCAB 953.7K
  • SYTA 1.9M
  • Earning Date
  • BCAB 11-06-2025
  • SYTA 11-13-2025
  • Dividend Yield
  • BCAB N/A
  • SYTA N/A
  • EPS Growth
  • BCAB N/A
  • SYTA N/A
  • EPS
  • BCAB N/A
  • SYTA N/A
  • Revenue
  • BCAB $11,000,000.00
  • SYTA N/A
  • Revenue This Year
  • BCAB N/A
  • SYTA $1.74
  • Revenue Next Year
  • BCAB N/A
  • SYTA $16.38
  • P/E Ratio
  • BCAB N/A
  • SYTA N/A
  • Revenue Growth
  • BCAB N/A
  • SYTA 49.13
  • 52 Week Low
  • BCAB $0.24
  • SYTA $0.93
  • 52 Week High
  • BCAB $2.53
  • SYTA $29.20
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 66.59
  • SYTA 59.84
  • Support Level
  • BCAB $0.63
  • SYTA $2.23
  • Resistance Level
  • BCAB $0.89
  • SYTA $3.92
  • Average True Range (ATR)
  • BCAB 0.07
  • SYTA 0.28
  • MACD
  • BCAB 0.00
  • SYTA 0.10
  • Stochastic Oscillator
  • BCAB 70.47
  • SYTA 50.00

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About SYTA Siyata Mobile Inc.

Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.

Share on Social Networks: